CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2025	Apr. 30, 2024
Income Statement [Abstract]
Revenue, Product and Service [Extensible Enumeration]	Service [Member]	Service [Member]
Oncology revenue	$ 56,944	$ 50,155
Costs and operating expenses:
Cost, Product and Service [Extensible Enumeration]	Service [Member]	Service [Member]
Cost of oncology revenue	$ 28,389	$ 29,401
Research and development	6,825	9,544
Sales and marketing	7,545	7,064
General and administrative	9,339	11,067
Loss on disposal of equipment	293	435
Total costs and operating expenses	52,391	57,511
Income (loss) from operations	4,553	(7,356)
Other income (expense):
Other income, net	73	48
Income (loss) before income tax expense	4,626	(7,308)
Benefit for income tax	(75)	(32)
Net income (loss)	$ 4,701	$ (7,276)
Net income (loss) per common share outstanding
basic (in dollars per share)	$ 0.34	$ (0.54)
diluted (in dollars per share)	$ 0.33	$ (0.54)
Weighted average common shares outstanding
basic (in shares)	13,659,786	13,547,604
diluted (in shares)	14,266,781	13,547,604